Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Varicose veins

6

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Possibly Marketed Outside US

4

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Lysyl oxidase homolog 2

4

Pancreatic triacylglycerol lipase

4

Protease

4

Vitamin K-dependent protein C

2

Vitamin K-dependent protein S

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase IV

4

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

4

1946

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

Secondary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Reiner, E.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

6

PUBCHEM

6

CAS

4

EPA CompTox

4

MERCK INDEX

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

VASOPROTECTIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIVARICOSE THERAPY

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Sclerosing agents for local injection

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TETRADECYL HYDROGEN SULFATE (ESTER)

6326W0DRHY

Export Data
Search for Structure

Status:

US Approved Rx (2004)

First approved in 1946

Class (Stereo):

CHEMICAL (MIXED)

Targets:

Vitamin K-dependent protein C

Vitamin K-dependent protein S

blood coagulation

Conditions:

Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. Sodium tetradecyl sulfate is the active component of the sclerosant drug Sotradecol. Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intra...

venous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent. Sotradecol® (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation. In the UK, Ireland, Italy, Australia, New Zealand and South Africa, it is sold under the trade-name Fibro-Vein in concentrations of 0.2%, 0.5%, 1.0%, and 3%

.BETA.-ESCIN SODIUM

2B56HTU5MJ

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Lysyl oxidase homolog 2

Pancreatic triacylglycerol lipase

Pancreatic triacylglycerol lipase

Conditions:

Chronic venous insufficiency

Lymphedema of arm

Aescin, the major active principle from Aesculus hippocastanum (Hippocastanaceae) the horse chestnut tree, has shown satisfactory evidence for a clinically significant activity in chronic venous insufficiency (CVI), haemorrhoids and post-operative oe...

dema. In one controlled trial aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI. The therapeutic benefit is well supported by a number of experimental investigations in different animal models, indicative of clearcut anti-oedematous, anti-inflammatory and venotonic properties, mainly related to the molecular mechanism of the agent, allowing improved entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions. Other mechanisms, i.e. release of PGF2 from veins, antagonism to 5-HT and histamine, reduced catabolism of tissue mucopolysaccharides, further underline the wide ranging mechanisms of the therapeutic activity of aescin. Aescin exists in two forms, α and β. β-aescin (b-escin) appears to be the active component of the mixture and is the molecular form present in major available pharmaceutical products. Beta-aescin has cytotoxic activity toward human colon adenocarcinoma cell lines.

SODIUM TETRADECYL SULFATE

Q1SUG5KBD6

Export Data
Search for Structure

Status:

US Approved Rx (2004)

First approved in 1946

Class (Stereo):

CHEMICAL (MIXED)

Targets:

Vitamin K-dependent protein C

Vitamin K-dependent protein S

blood coagulation

Conditions:

Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. Sodium tetradecyl sulfate is the active component of the sclerosant drug Sotradecol. Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intra...

venous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent. Sotradecol® (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation. In the UK, Ireland, Italy, Australia, New Zealand and South Africa, it is sold under the trade-name Fibro-Vein in concentrations of 0.2%, 0.5%, 1.0%, and 3%

.ALPHA.-ESCIN SODIUM

58G9ZMJ34D

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Lysyl oxidase homolog 2

Pancreatic triacylglycerol lipase

Pancreatic triacylglycerol lipase

Conditions:

Chronic venous insufficiency

Lymphedema of arm

Aescin, the major active principle from Aesculus hippocastanum (Hippocastanaceae) the horse chestnut tree, has shown satisfactory evidence for a clinically significant activity in chronic venous insufficiency (CVI), haemorrhoids and post-operative oe...

dema. In one controlled trial aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI. The therapeutic benefit is well supported by a number of experimental investigations in different animal models, indicative of clearcut anti-oedematous, anti-inflammatory and venotonic properties, mainly related to the molecular mechanism of the agent, allowing improved entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions. Other mechanisms, i.e. release of PGF2 from veins, antagonism to 5-HT and histamine, reduced catabolism of tissue mucopolysaccharides, further underline the wide ranging mechanisms of the therapeutic activity of aescin. Aescin exists in two forms, α and β. β-aescin (b-escin) appears to be the active component of the mixture and is the molecular form present in major available pharmaceutical products. Beta-aescin has cytotoxic activity toward human colon adenocarcinoma cell lines.

.ALPHA.-ESCIN

LB5DJT9FIW

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Lysyl oxidase homolog 2

Pancreatic triacylglycerol lipase

Pancreatic triacylglycerol lipase

Conditions:

Chronic venous insufficiency

Lymphedema of arm

Aescin, the major active principle from Aesculus hippocastanum (Hippocastanaceae) the horse chestnut tree, has shown satisfactory evidence for a clinically significant activity in chronic venous insufficiency (CVI), haemorrhoids and post-operative oe...

dema. In one controlled trial aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI. The therapeutic benefit is well supported by a number of experimental investigations in different animal models, indicative of clearcut anti-oedematous, anti-inflammatory and venotonic properties, mainly related to the molecular mechanism of the agent, allowing improved entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions. Other mechanisms, i.e. release of PGF2 from veins, antagonism to 5-HT and histamine, reduced catabolism of tissue mucopolysaccharides, further underline the wide ranging mechanisms of the therapeutic activity of aescin. Aescin exists in two forms, α and β. β-aescin (b-escin) appears to be the active component of the mixture and is the molecular form present in major available pharmaceutical products. Beta-aescin has cytotoxic activity toward human colon adenocarcinoma cell lines.

.BETA.-ESCIN

QYK0D6H79O

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Lysyl oxidase homolog 2

Pancreatic triacylglycerol lipase

Pancreatic triacylglycerol lipase

Conditions:

Chronic venous insufficiency

Lymphedema of arm

Aescin, the major active principle from Aesculus hippocastanum (Hippocastanaceae) the horse chestnut tree, has shown satisfactory evidence for a clinically significant activity in chronic venous insufficiency (CVI), haemorrhoids and post-operative oe...

dema. In one controlled trial aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI. The therapeutic benefit is well supported by a number of experimental investigations in different animal models, indicative of clearcut anti-oedematous, anti-inflammatory and venotonic properties, mainly related to the molecular mechanism of the agent, allowing improved entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions. Other mechanisms, i.e. release of PGF2 from veins, antagonism to 5-HT and histamine, reduced catabolism of tissue mucopolysaccharides, further underline the wide ranging mechanisms of the therapeutic activity of aescin. Aescin exists in two forms, α and β. β-aescin (b-escin) appears to be the active component of the mixture and is the molecular form present in major available pharmaceutical products. Beta-aescin has cytotoxic activity toward human colon adenocarcinoma cell lines.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1